Thu, 03 Nov 2016 08:00:00 EDTMethods are disclosed for determining a level of endothelial disease in a subject. The methods comprise examining circulating endothelial cells from the subject for the presence of one or more coagulation factors and correlating an amount of circulating endothelial cells exhibiting one or more coagulation factors with the level of endothelial disease in the subject. Anti-coagulation factor therapy can then be administered to the subject to address the endothelial disease.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to new and/or improved methods of identification and selection of cardiomyocytes from human embryonic stem (hES) cells. The method further comprises isolating the selected cardiomyocyte population. There is also provided method for the screening for cardiovascular compounds comprising subjecting the said cardiomyocyte population to test compound/s, and observing and/or interpreting a response of the cardiomyocytes to the test compound.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed herein is a method of detecting antigen specific T cells in a sample isolated from a subject and mapping immunostimulatory epitopes of the antigen. Such methods may be used in methods of making antigen specific T cell compositions, e.g., for the treatment of diseases such as cancer, infectious diseases and autoimmune disorders.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to a polypeptide comprising an antigenic fragment having a sequence of at least seven amino acids from a hydrophilic domain of an oil body-associated protein, wherein the polypeptide comprises a truncated hydrophobic domain of the oil body-associated protein or does not comprise such a domain, and wherein the oil body-associated protein is selected from the group comprising oleosin, caleosin and steroleosin, to a pharmaceutical composition or a vaccine comprising the polypeptide, to a complex comprising the polypeptide and an antibody bound thereto, to a medical or diagnostic device comprising the polypeptide, to a nucleic acid encoding the polypeptide or a cell comprising said nucleic acid, to a test kit comprising the polypeptide, and to a method for detecting an antibody which binds to the polypeptide.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.
Thu, 03 Nov 2016 08:00:00 EDTThe current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a KRT5, KRT7, NapsinA, TTF1, TP63, and MUC1 fragment peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides markers of regulatory T (Treg) cells, preferably, cell surface markers of Treg cells and uses of those markers or compounds that bind thereto to identify or isolate Treg cells or to diagnose/prognose/treat/prevent Treg-mediated conditions. The present invention also provides methods for identification and/or isolation of Treg cell subpopulations and such isolated subpopulations of Treg cells.
Thu, 03 Nov 2016 08:00:00 EDTA method of assaying or monitoring the determining immunological competence of a subject, particularly for determining immunological competence in a subject, including but not limited to a transplant recipient, is provided. The method comprises measuring the levels of antibodies in a sample obtained from a subject to poly-guanine oligonucleotides.
Thu, 03 Nov 2016 08:00:00 EDTGlomus iranicum var. tenuihypharum var. nov. strain deposited under BCCM deposit number 54871, comprising the sequence identified by SEQ ID NO: 1; composition comprising said strain, 2:1 smectite clays, metal ions and chitin and use thereof as bio-nematicide. The invention also discloses a composition comprising said strain, fungicides, bio-fungicides, insecticides, bio-insecticides, nematicides and bio-nematicides.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a method for diagnosing nasopharyngeal cancer in a subject by detecting UBR5-ZNF423 fusion polypeptide or polynucleotide, which is in some cases due to a gene fusion of UBR5-ZNF423. A kit useful for such a method is also provided. In addition, the present invention provides a method for treating nasopharyngeal cancer by eliminating UBR5-ZNF423 gene expression or activity.
Thu, 03 Nov 2016 08:00:00 EDTA method for at least one of characterizing, diagnosing, and treating an endocrine system condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the endocrine system condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the endocrine system condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure relates to a method of making an adenovirus plasmid comprising a part or all of an adenovirus genome and one or more original restriction sites allowing rapid and flexible manipulation of the adenovirus genome, and methods of preparing adenovirus constructs, for example comprising a transgene. The disclosure also extends to novel intermediates employed in and generated by the method, to plasmids and shuttle vectors of the method and to adenoviruses or adenoviral vectors obtainable from the plasmid and/or method. The disclosure further relates to use of the viruses or vectors, for example obtained from a method disclosed herein, in therapy, such as use in the treatment of cancer.
Thu, 03 Nov 2016 08:00:00 EDTThe invention relates to a multilayered nanoparticle for delivery of RNA to a cell and methods of manufacturing and using the same. The multilayered nanoparticle has a core nanoparticle coated by alternating positively and negatively charged polymer layers, wherein the at least one of the negatively charged polymer layers is RNA.
Thu, 03 Nov 2016 08:00:00 EDTEngineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
Thu, 03 Nov 2016 08:00:00 EDTEngineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
Thu, 03 Nov 2016 08:00:00 EDTThe invention relates to compositions and methods of constructs comprising a SIRP-α polypeptide, including SIRP-α variants. The constructs may be engineered in a variety of ways to respond to environmental factors, such as pH, hypoxia, and/or the presence of tumor-associated enzymes or tumor-associated antigens. The constructs of the invention may be used to treat various diseases, such as cancer, preferably solid tumor or hematological cancer.
Thu, 03 Nov 2016 08:00:00 EDTIn certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
Thu, 03 Nov 2016 08:00:00 EDTProvided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an α/β small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
Thu, 03 Nov 2016 08:00:00 EDTA composition comprising a surfactant and an amount of potassium chloride to impart pearlescence.
Thu, 03 Nov 2016 08:00:00 EDTIt is one of the objects of the present disclosure to provide zinc oxide particles having improved ultraviolet shielding performance especially in the region of UV-A radiation at 400 to 320 nm. A cerium oxide-coated zinc oxide particle comprising a matrix raw zinc oxide particle and a cerium oxide layer formed on the surface of the matrix particle, wherein a cerium oxide amount is 5 to 30 wt % relative to 100 wt % of the zinc oxide, a particle diameter of the cerium oxide-coated zinc oxide particles is 0.01 μm or more, and a specific surface area of the cerium oxide-coated zinc oxide particle is 5.0 m2/g or more.
Thu, 03 Nov 2016 08:00:00 EDTA material for medical purposes based on polyacrylamide hydrogel contains in mass %: acrylamide 0.9-8.2%, N,N′ methylene-bis-acrylamide —0.1-1.8%, hyaluronic acid −0.1-2.0%, and water-up to 100.0%. In one of the embodiments of the method, the novel material is produced by copolymerization of the components in an inert gas medium in the presence of a peroxide polymerization activator at 69-74° C. for 16-19 hours. In another embodiment, hyaluronic acid hydrogel is mixed in the inert gas medium to a homogenous substance with a polyacrylamide suitable for medicine, which is produced from relevant amounts of acrylamide and N,N′-methylen-bis-acrylamide and water in the presence of a peroxide polymerization activator.
Thu, 03 Nov 2016 08:00:00 EDTA process is provided for inhibiting symptoms of celiac disease, Clostridium difficile associated diseases such as Clostridium difficile colitis, pseudomembranous colitis and antibiotic associated diarrhea, food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgM. When administered in a, therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.
Thu, 03 Nov 2016 08:00:00 EDTThe presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to recombinant Clostridium difficile antigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of a C. difficile Toxin A sequence or a C. difficile Toxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851-2710 of C. difficile Toxin A and/or residues 1853-2366 of a C. difficile Toxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/treatment/suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to multispecific antibodies based on antibodies that share a common light chain. The multispecific antibodies include modified heavy chains comprising by domain exchange a common light chain variable domain VL; and two modified light chains comprising by domain exchange variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of said antibodies and their use.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention is based, at least in part, on the discovery that PDK1 is associated with the outer plasma membrane of the cell. Accordingly, the present invention encompasses 3-phosphoinositide-dependent protein kinase-1 (PDK1) binding molecules, such as an antibody. The binding molecules of the invention are useful for detecting PDK1 and for inhibiting PDK1 activity, e.g., in a human subject having a disorder in which PDK1 activity is detrimental, such as a cancer.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.
Thu, 03 Nov 2016 08:00:00 EDTThe disclosure relates in some aspects to methods of treating and diagnosing αVβ6 overexpressing cancer. In some embodiments, the disclosure relates to methods of treating and diagnosing αVβ6 and HER2 overexpressing cancer. In some embodiments, combination therapy strategies are employed.
Thu, 03 Nov 2016 08:00:00 EDTProvided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.
Thu, 03 Nov 2016 08:00:00 EDTAntibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.
Thu, 03 Nov 2016 08:00:00 EDTMethods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates generally to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies. In one aspect, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties for use in methods of treating neuroma and/or bone associated pain.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
Thu, 03 Nov 2016 08:00:00 EDT[Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2. [Means for Solution] The present inventors have investigated anti-human BDCA-2 antibodies, and as a result, they have provided an anti-human BDCA-2 antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 109 of SEQ ID NO: 4, a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 6 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 8, and a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 122 of SEQ ID NO: 10 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 12.
Thu, 03 Nov 2016 08:00:00 EDTThis invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.
Thu, 03 Nov 2016 08:00:00 EDTThe invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.
Thu, 03 Nov 2016 08:00:00 EDTA pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
Thu, 03 Nov 2016 08:00:00 EDTAntibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
Thu, 03 Nov 2016 08:00:00 EDTThe invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to methods for treating inflammatory bowel disease and other indications by inhibiting leptin activity.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a vaccine against IL-17A, which uses, as an immunogen, a polypeptide containing the amino acid sequence shown in SEQ ID NO: 1, or an amino acid sequence derived from a non-human mammal, which corresponds to SEQ ID NO: 1, a prophylactic or therapeutic agent containing the vaccine for diseases involving IL-17A as an aggravation factor, and the like.
Thu, 03 Nov 2016 08:00:00 EDTPurified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
Thu, 03 Nov 2016 08:00:00 EDTThe invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects.
Thu, 03 Nov 2016 08:00:00 EDTProvided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.
Thu, 03 Nov 2016 08:00:00 EDTMethods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided in which a subject having FOP is administered an effective regime of an antibody against Activin B, BMP9 or BMP10.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure provides a method of treating wound healing in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.
Thu, 03 Nov 2016 08:00:00 EDTSubject matter of the present invention is an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold binding to the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2 for use in a therapy of cancer. Subject matter of the present invention is anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment of cancer according to claim 1 wherein said anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold requires the presence of a C-terminally amidated tyrosine residue within the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2, for binding.
Thu, 03 Nov 2016 08:00:00 EDTIsolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human β-amyloid peptide as compare to low molecular weight forms of β-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of β-amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
Thu, 03 Nov 2016 08:00:00 EDTThis invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
Thu, 03 Nov 2016 08:00:00 EDTA method of treating a complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof, in a subject in need thereof, the method comprising of administering to the subject a therapeutically effective amount of an antibody which inhibits the alternative complement pathway, wherein the antibody administered is effective for inhibiting complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof.
Thu, 03 Nov 2016 08:00:00 EDTThis invention features methods and compositions useful for treating and diseases caused by a dysregulation of the BMP/GDF branch of the TGF-β signaling pathway. Also disclosed are methods for identifying compounds useful for such therapy.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention in the fields of immunology and infectious diseases relates to opsonic and protective antibodies that are specific for Gram-positive bacteria, particularly to carbohydrate structures exposed on the surface of the bacteria. The invention includes monoclonal and chimeric antibodies, as well as fragments, regions and derivatives thereof. This invention also relates to the epitope to which the antibodies of the invention bind as well as the sequences, fragments, and regions of the epitopes. Both the antibodies and peptides that encompass the epitope, and regions and fragments thereof, may be used for diagnostic, prophylactic and therapeutic applications.
Thu, 03 Nov 2016 08:00:00 EDTThis invention relates generally to molecules that specifically bind bacterial V-tip proteins of the type III secretion system of Gram negative bacteria such as PcrV from Pseudomonas aeruginosa. More specifically, this invention relates to molecules that block the injection of effector molecules into target cells. This invention also relates to molecules that specifically bind to bacterial lipoproteins, such as OprI. The molecules of the present invention are monospecific or multispecific and can bind their target antigen in a monovalent or multivalent manner. The invention also relates generally to molecules that specifically bind bacterial cell surface proteins such as OprI, and to methods of use these molecules in a variety of therapeutic, diagnostic, and/or prophylactic indications.
Thu, 03 Nov 2016 08:00:00 EDTDescribed herein are methods of preventing and/or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA.
Thu, 03 Nov 2016 08:00:00 EDTAn isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain; wherein the isoform is a TGFβ-1 agonist. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a T cell receptor (TCR) having the property of binding to ALWGPDPAAA (derived from human pre-pro insulin (PPI) protein) HLA-A*02 complex and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain. Also provided are nucleic acids encoding the TCR and cells engineered to present the TCR. Therapeutic agents based on TCRs of the invention can be used for the purpose of delivering immunosuppressive agents to beta cells in order to prevent their destruction by CD8+ T cells.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the IL-15Rα or derivatives thereof; and uses thereof.
Thu, 03 Nov 2016 08:00:00 EDTThis disclosure relates to a GM-CSF and IL-4 conjugate fused to a glycolipid (GPI)-anchoring sequence that is incorporated into chimeric virus-like particles (VLPs) enriched with a viral protein, e.g., viral envelope protein or HIV envelope protein. In certain embodiments, the disclosure relates to methods of immunization with the chimeric VLPs disclosed herein. In certain embodiments, the disclosure relates to methods of immunization with disclosed HIV antigen containing VLPs through an intramuscular priming-intranasal boosting immunization route.
Thu, 03 Nov 2016 08:00:00 EDTIn certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.
Thu, 03 Nov 2016 08:00:00 EDTThe present application relates to solid state forms, for example, crystalline forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
Thu, 03 Nov 2016 08:00:00 EDTThis document discloses molecules having the following formula (“Formula One”): and processes related thereto.
Thu, 03 Nov 2016 08:00:00 EDTProvided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): where the structural variables are as defined herein.
Thu, 03 Nov 2016 08:00:00 EDTProvided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of hydrogen peroxide and are therefore selective anti-cancer therapeutics for cancers associated with elevated reactive oxygen species (ROS). Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.
Thu, 03 Nov 2016 08:00:00 EDTProstacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C2-C18 alkyl, branched C3-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described, for example, for administration via subcutaneous or intravenous infusion to a patient in need of pulmonary hypertension treatment. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom.
Thu, 03 Nov 2016 08:00:00 EDTA sea water harvesting process includes the steps of collecting sea water, filtering the sea water, passing the filtered sea water through a high-pressure reverse osmosis membrane to separate the sea water into de-salinated water and concentrated sea water, delivering the concentrated sea water to an evaporator, heating the concentrated sea water in the evaporator under vacuum to produce calcium sulphate, sea salt and a super-concentrated sea water. Downstream of the evaporator the super-concentrated sea water is heated to produce a concentrated mineral liquor containing sea minerals in a concentration of about 42%.
Thu, 03 Nov 2016 08:00:00 EDTA method of preparing graphene includes supplying a gas on a metal catalyst, the gas including CO2, CH4, and H2O, and reacting and cooling the resultant.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention relates to microcapsules with a core-shell or matrix morphology stabilized by cross-linked nanoparticles. A process for the preparation of said microcapsules comprising selecting internal crosslinking of a Pickering emulsion is also an object of the invention. Perfumed consumer products, in particular fine fragrance, home and personal care products are also part of the invention.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure provides medical devices possessing reactants thereon, which further promote adherence of the device to tissue in vivo and/or release of bioactive agents from the device.
Thu, 03 Nov 2016 08:00:00 EDTThe invention relates to methods of preparing a bone matrix solution, a bone matrix implant, and variants thereof. The invention also relates to methods of cell culture using the same. The invention further relates to bone matrix scaffolds comprising one or more bone matrix nanofibers, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells and promoting differentiation of stem cells using the same.
Thu, 03 Nov 2016 08:00:00 EDTThe invention provides tissue repair compositions and methods of making the tissue repair compositions. Also featured are methods of treatment using the tissue repair compositions and articles of manufacture that include the tissue repair compositions.
Thu, 03 Nov 2016 08:00:00 EDTA scaffold may comprise a first polymeric electrospun fiber comprising a first material having a first degradation rate, and a second polymeric electrospun fiber comprising a second material having a second degradation rate different from the first degradation rate. The first degradation rate may substantially correspond to a cell infiltration rate, and the second degradation rate may be slower than the first degradation rate. Such a scaffold may be manufactured by electrospinning a first polymer fiber having a first degradation rate by ejecting a first polymer solution from a first polymer injection system onto a mandrel, and electrospinning a second polymer fiber having a second degradation rate different from the first degradation rate by ejecting a second polymer solution from a second polymer injection system onto a mandrel. Wound healing may be improved by applying such a scaffold to a portion of a wound.
Thu, 03 Nov 2016 08:00:00 EDTThe invention provides methods and compositions for wound treatment and/or blood clot formation, e.g., arresting the flow of blood from an open wound. The methods and compositions provide for promoting and accelerating wound healing and optionally provide for inhibition of microbial infection and/or a local analgesic effect.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a biodegradable medical adhesive or a sealant composition containing an oxidized glycosaminoglycan and a polyamine. The composition of the present invention exhibits improved effects in biodegradation, coating property, gelation time, hemostatic capacity, adhesive force, moisture absorptive capacity and the like, and thus can be applied to various medical uses in which a medical adhesive or sealant can be used, such as biotissue adhesion, filling, coating, adhesion prevention, wound covering, leakage prevention and hemostasis.
Thu, 03 Nov 2016 08:00:00 EDTOne aspect of the invention relates to use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning in a mammal. Another aspect of the invention relates to a method of 5gastrointestinal mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal mucosa in a mammal an effective amount of a composition comprising a purified inverse thermosensitive polymer; and surgically resecting said region of gastrointestinal mucosa. Yet another aspect of the invention relates to a kit for use in gastrointestinal endoscopic mucosal resectioning in a mammal, comprising a composition 10comprising a purified inverse thermosensitive polymer; a syringe; and instructions for use thereof.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.
Thu, 03 Nov 2016 08:00:00 EDTSilicone adhesive dressings that are antimicrobial and can include a backing layer are for use on wound areas and surgical incisions and as a protective dressing to cover, for example, indwelling therapeutic devices. The dressings include polyhexamethylene biguanide (PHMB) and ethylenediamine tetraacetic acid (EDTA) in a silicone layer as particulates, and optionally include glycerin.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a hemostatic porous composite sponge comprising: i) a matrix of a biomaterial; andii) one hydrophilic polymeric component comprising reactive groupswherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained,wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, orsaid matrix is impregnated with said polymeric material, orboth.
Thu, 03 Nov 2016 08:00:00 EDTThe present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
Thu, 03 Nov 2016 08:00:00 EDTCopper-catalyzed radiofluorination of aryl iodides using Ag18F, methods of preparing Ag18F, and compounds obtained by copper-catalyzed radiofluorination of aryl iodides using Ag18F are disclosed. Diagnostic and therapeutic methods involving such compounds also are disclosed.
Thu, 03 Nov 2016 08:00:00 EDTThe present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.
Thu, 03 Nov 2016 08:00:00 EDTThe present disclosure describes the role for miR-322(424)/503 in the differentiation of cardiac precursor cells. Thus, the use of these molecules in the programming of resident stem/progenitor cells into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.
Thu, 03 Nov 2016 08:00:00 EDTA lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.
Thu, 03 Nov 2016 08:00:00 EDTThe invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a group of novel SMA derivatives and a covalent conjugate of the derivatives and an active substance. More specifically, the present invention provides: an SMA derivative which contains (i) a styrene-maleic acid copolymer (SMA) and (ii) a side chain (b) that contains a functional group (a) selected from among —NH2, —SH, —OH, —COOH, —NH—(C═NH)—NH2 and —C(CH2—OH)3 and introduced into a carboxyl group of a maleic acid residue of the SMA via an amide bond or an ester bond, and wherein when a plurality of side chain (b) is introduced into the SMA, the side chains (b) may be identical or different from each other; and a conjugate of this SMA derivative and an active substance.
Thu, 03 Nov 2016 08:00:00 EDTProvided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.
Thu, 03 Nov 2016 08:00:00 EDTDisclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.
Thu, 03 Nov 2016 08:00:00 EDTThe invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Thu, 03 Nov 2016 08:00:00 EDTA sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent;viral particles or a physiologically active polypeptide;an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; andoptionally, one or more sugars.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent delivered in combination with the fluorochemical composition.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a combination epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia, wherein the epigenetic factor is selected from the group consisting of histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) I inhibitors, hydroxyurea, Granulocyte-Colony Stimulating Factor (G-CSF), histone demethylase inhibitors and ATRA (All Trans-retinoic acid). Accordingly, the invention provides a pharmaceutical composition comprising a CD33 targeting compound and at least one epigenetic factor and an epigenetic factor for use in the amelioration and/or treatment of a myeloid leukemia, wherein the epigenetic factor increases the responsiveness of a patient to a CD33 targeting compound. Moreover, the invention provides the use of at least one an epigenetic factor for increasing the responsiveness of a myeloid leukemia patient to a treatment with a CD33 targeting compound, a method for the treatment of a myeloid leukemia, the method comprising the administration of at least one epigenetic factor and a CD33 targeting compound to a patient in the need thereof and a kit comprising a pharmaceutical composition of the invention or an epigenetic factor of the invention and a bispecific CD33 targeting compound.
Thu, 03 Nov 2016 08:00:00 EDTThe present invention provides a combination of an antibody binding to a fibroblast growth factor receptor, and another agent.